Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,632 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study.
Borelli B, Fontana E, Giordano M, Antoniotti C, Lonardi S, Bergamo F, Pietrantonio F, Morano F, Tamburini E, Boccaccino A, Santini D, Zucchelli G, Pella N, Maiello E, Passardi A, Zaniboni A, Ugolini C, Fontanini G, Falcone A, Nyamundanda G, Sadanandam A, Cremolini C. Borelli B, et al. Among authors: giordano m. ESMO Open. 2021 Apr;6(2):100073. doi: 10.1016/j.esmoop.2021.100073. Epub 2021 Mar 3. ESMO Open. 2021. PMID: 33676295 Free PMC article.
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini C. Boccaccino A, et al. Among authors: giordano m. ESMO Open. 2022 Jun;7(3):100506. doi: 10.1016/j.esmoop.2022.100506. Epub 2022 Jun 10. ESMO Open. 2022. PMID: 35696748 Free PMC article. Clinical Trial.
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
Raimondi A, Di Maio M, Morano F, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Sartore-Bianchi A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Adamo V, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Bergamo F, Niger M, Antista M, Peverelli G, de Braud F, Di Bartolomeo M, Pietrantonio F. Raimondi A, et al. Among authors: giordano m. Eur J Cancer. 2020 Aug;135:230-239. doi: 10.1016/j.ejca.2020.04.048. Epub 2020 Jul 2. Eur J Cancer. 2020. PMID: 32623288 Free article. Clinical Trial.
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.
Raimondi A, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Amatu A, Tampellini M, Racca P, Murialdo R, Clavarezza M, Zaniboni A, Toscano G, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Niger M, Antista M, Ambrosini M, Pagani F, Prisciandaro M, Randon G, de Braud F, Di Bartolomeo M, Pietrantonio F, Morano F. Raimondi A, et al. Among authors: giordano m. Support Care Cancer. 2021 Jul;29(7):3971-3980. doi: 10.1007/s00520-020-05972-2. Epub 2021 Jan 3. Support Care Cancer. 2021. PMID: 33392769 Clinical Trial.
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial.
Raimondi A, Randon G, Prisciandaro M, Pagani F, Lonardi S, Antoniotti C, Bozzarelli S, Sartore-Bianchi A, Tampellini M, Fanchini L, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M, Petrelli F, Antonuzzo L, Giordano M, Rossi A, Di Bartolomeo M, Di Maio M, Pietrantonio F, Morano F. Raimondi A, et al. Among authors: giordano m. Int J Cancer. 2022 Nov 15;151(10):1760-1769. doi: 10.1002/ijc.34156. Epub 2022 Jun 23. Int J Cancer. 2022. PMID: 35678328
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F; GISCAD investigators. Cascinu S, et al. Among authors: giordano m. Eur J Cancer. 2017 Sep;83:106-115. doi: 10.1016/j.ejca.2017.06.029. Epub 2017 Jul 20. Eur J Cancer. 2017. PMID: 28735067 Clinical Trial.
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F. Pietrantonio F, et al. Among authors: giordano m. JAMA Oncol. 2019 Sep 1;5(9):1268-1275. doi: 10.1001/jamaoncol.2019.1467. JAMA Oncol. 2019. PMID: 31268481 Free PMC article.
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, Banzi M, Zaniboni A, Pasini F, Bozzarelli S, Garattini SK, Ferrari D, Montesarchio V, Mambrini A, Ciuffreda L, Galli F, Pusceddu V, Carlomagno C, Bidoli P, Amoroso D, Bochicchio AM, Frassineti L, Corsi D, Bilancia D, Pastorino A, De Stefano A, Labianca R; TOSCA (Three or Six Colon Adjuvant) investigators. Rosati G, et al. Eur J Cancer. 2021 May;148:190-201. doi: 10.1016/j.ejca.2021.01.051. Epub 2021 Mar 18. Eur J Cancer. 2021. PMID: 33744715
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.
Procopio G, Chiuri VE, Giordano M, Alitto AR, Maisano R, Bordonaro R, Cinieri S, Rossetti S, De Placido S, Airoldi M, Galli L, Gasparro D, Ludovico GM, Guglielmini PF, Carella C, Nova P, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D; ABItude Study Group. Procopio G, et al. Among authors: giordano m. ESMO Open. 2022 Apr;7(2):100431. doi: 10.1016/j.esmoop.2022.100431. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405438 Free PMC article.
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.
Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, Cappuzzo F, Grossi F, Santo A, Cortinovis D, Favaretto A, Lorusso V, Galetta D, Siena S, Bettini A, Iurlaro M, Caprioli A; LIFE study team. Gridelli C, et al. J Cancer Res Clin Oncol. 2014 Oct;140(10):1783-93. doi: 10.1007/s00432-014-1715-2. Epub 2014 Jun 6. J Cancer Res Clin Oncol. 2014. PMID: 24903964 Free article.
1,632 results